In comparison to commercial HPV vaccines, such as Gardasil‐9, which are on the basis of VLPs originated from L1 proteins and primarily elicit L1‐specific neutralising bodies to prevent infection,51 the Ad‐E6/7‐HR vaccine targets E6 and E7 proteins and confers protection mainly through specific cellular immunity, enabling it not only prevent infection but also treat HPV‐driven malignancies, positioning it a viable option for application in established cancers. This evidence concerns the gene HR and infection.